NCG Group

Active Biotech upgrade to BizView for their performance management and reporting

Pressmeddelande   •   Dec 16, 2013 14:30 CET

ACTIVE BIOTECH has for many years been using NCG Group's software products and has now decided to go over to BizView. BizView interact with Jeeves in reporting, analysis, forecasting and consolidation.

For more information contact: ulf.olsson@ncg-group.com

About BizView and NCG Group

BizView is one of the leading systems for forecasting, budgeting and reporting in the Nordic countries. The software provides a web-based Excel-like user interface combined with powerful workflow management. BizView is an open solution that also fits well with QlikView’s and Microsoft’s business intelligence offerings. BizView is developed and marketed by NCG Group with offices in Stockholm, Oslo and development in Skellefteå. NCG Group has more than 500 customers where over 1000 companies use our solutions.

For more information see www.ncg-group.com

About Active Biotech

Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. In pivotal phase is laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis. Also tasquinimod for the treatment of prostate cancer, with a unique mode of action, is in pivotal phase. In addition, laquinimod has concluded Phase II development for Crohn's and Lupus. The company has two additional projects in clinical development, ANYARA primarily for the treatment of renal cell cancer and the orally administered compound paquinimod (57-57) for systemic sclerosis.

Please visit www.activebiotech.com for more information.